Alpha 2.0
Login Register
» Authors » Ken Page

Ken Page

Explore the profile of Ken Page including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 489
Followers 0
Related Specialties
Biochemistry
Chemistry
Nursing
Top 10 Co-Authors
Linette Ruston
Sabina Cosulich
Martina Fitzek
Benedicte Delouvrie
Craig S Harris
Gilles Ouvry
Andrew D Morley
Kevin Hudson
Attilla Ting
Bernard Barlaam
Published In
Bioorg Med Chem Lett
J Med Chem
Chem Res Toxicol
Hum Factors Health
Chem Biol Interact
Affiliations
Soon will be listed here.
Recent Articles
1.
Decontamination and reuse of personal protective masks and respirators in healthcare: Human-centered investigation and implementation considerations
Simmons S, Page K, Davies J, Malott R, Conly J
Hum Factors Health . 2022 May; 1:100003. PMID: 35620552
No abstract available.
2.
Addressing personal protective equipment (PPE) decontamination: Methylene blue and light inactivates severe acute respiratory coronavirus virus 2 (SARS-CoV-2) on N95 respirators and medical masks with maintenance of integrity and fit
Lendvay T, Chen J, Harcourt B, Scholte F, Lin Y, Kilinc-Balci F, et al.
Infect Control Hosp Epidemiol . 2021 May; 43(7):876-885. PMID: 34016200
Objective: The coronavirus disease 2019 (COVID-19) pandemic has resulted in shortages of personal protective equipment (PPE), underscoring the urgent need for simple, efficient, and inexpensive methods to decontaminate masks and...
3.
Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors
Barlaam B, Cosulich S, Fitzek M, Germain H, Green S, Hanson L, et al.
Bioorg Med Chem Lett . 2017 May; 27(13):3030-3035. PMID: 28526367
We report the discovery of a novel aminopyrazine series of PI3Kα inhibitors, designed by hybridizing two known scaffolds of PI3K inhibitors. We describe the progress achieved from the first compounds...
4.
Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers
Barlaam B, Cosulich S, Delouvrie B, Ellston R, Fitzek M, Germain H, et al.
Bioorg Med Chem Lett . 2015 Oct; 25(22):5155-62. PMID: 26475521
Starting from potent inhibitors of PI3Kα having poor general kinase selectivity (e.g., 1 and 2), optimisation of this series led to the identification of 25, a potent inhibitor of PI3Kα...
5.
Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold
Barlaam B, Cosulich S, Fitzek M, Green S, Harris C, Hudson K, et al.
Bioorg Med Chem Lett . 2015 May; 25(13):2679-85. PMID: 25980912
Starting from compound 1, a potent PI3Kα inhibitor having poor general kinase selectivity, we used structural data and modelling to identify key exploitable differences between PI3Kα and the other kinases....
6.
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases
Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies B, et al.
J Med Chem . 2013 Feb; 56(5):2059-73. PMID: 23394218
Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against...
7.
Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity
Foote K, Blades K, Cronin A, Fillery S, Guichard S, Hassall L, et al.
J Med Chem . 2013 Feb; 56(5):2125-38. PMID: 23394205
ATR is an attractive new anticancer drug target whose inhibitors have potential as chemo- or radiation sensitizers or as monotherapy in tumors addicted to particular DNA-repair pathways. We describe the...
8.
In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs
Thompson R, Isin E, Li Y, Weidolf L, Page K, Wilson I, et al.
Chem Res Toxicol . 2012 Jun; 25(8):1616-32. PMID: 22646477
Idiosyncratic adverse drug reactions (IADRs) in humans can result in a broad range of clinically significant toxicities leading to attrition during drug development as well as postlicensing withdrawal or labeling....
9.
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background
Davies B, Greenwood H, Dudley P, Crafter C, Yu D, Zhang J, et al.
Mol Cancer Ther . 2012 Feb; 11(4):873-87. PMID: 22294718
AKT is a key node in the most frequently deregulated signaling network in human cancer. AZD5363, a novel pyrrolopyrimidine-derived compound, inhibited all AKT isoforms with a potency of 10 nmol/L...
10.
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2
De Savi C, Morley A, Nash I, Karoutchi G, Page K, Ting A, et al.
Bioorg Med Chem Lett . 2011 Dec; 22(1):271-7. PMID: 22153941
Directed screening has identified a novel series of non-zinc binding MMP13 inhibitors that possess good levels of activity whilst demonstrating excellent selectivity over related MMPs. A lead optimisation campaign has...